Novartis is pleased to announce FDA approval of SCEMBLIX for adults with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).

FDA approval was based on results from ASC4FIRST, a multicenter, randomized, active-controlled, open-label study that evaluated SCEMBLIX vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) (bosutinib, dasatinib, imatinib, nilotinib) in adult patients with newly diagnosed Ph+ CML-CP.

Read More.